DC vesicles are expected to precisely and effectively deliver IL-15 to tumor-specific T cells: (1) the molecular components of biNV are similar to living DCs, including surface expression of major histocompatibility complex (MHC) I/antigenic peptide complexes and costimulatory molecules32, (2) the cell-free biNV minimizes the cellular therapy-related risks such as in vivo replication, (3) biNV displays extensive distribution in lymph nodes due to suitable size (110 nm) and abundant surface membrane receptors. The gene discussed is IL15; the disease is neoplasm.